<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncol Lett</journal-id><journal-id journal-id-type="iso-abbrev">Oncol Lett</journal-id><journal-id journal-id-type="publisher-id">OL</journal-id><journal-title-group><journal-title>Oncology Letters</journal-title></journal-title-group><issn pub-type="ppub">1792-1074</issn><issn pub-type="epub">1792-1082</issn><publisher><publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27123117</article-id><article-id pub-id-type="pmc">4841051</article-id><article-id pub-id-type="doi">10.3892/ol.2016.4394</article-id><article-id pub-id-type="publisher-id">OL-0-0-4394</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Comparison of recovery effect for sufentanil and remifentanil anesthesia with TCI in laparoscopic radical resection during colorectal cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>QI</surname><given-names>YANYAN</given-names></name><xref ref-type="aff" rid="af1-ol-0-0-4394"/></contrib><contrib contrib-type="author"><name><surname>YAO</surname><given-names>XIANGYAN</given-names></name><xref ref-type="aff" rid="af1-ol-0-0-4394"/></contrib><contrib contrib-type="author"><name><surname>ZHANG</surname><given-names>BEIBEI</given-names></name><xref ref-type="aff" rid="af1-ol-0-0-4394"/></contrib><contrib contrib-type="author"><name><surname>DU</surname><given-names>XIANHUI</given-names></name><xref ref-type="aff" rid="af1-ol-0-0-4394"/><xref rid="c1-ol-0-0-4394" ref-type="corresp"/></contrib></contrib-group><aff id="af1-ol-0-0-4394">Department of Anesthesiology, Henan Provincial People's Hospital, Zhengzhou, Henan 450003, P.R. China</aff><author-notes><corresp id="c1-ol-0-0-4394"><italic>Correspondence to</italic>: Dr Xianhui Du, Department of Anesthesiology, Henan Provincial People's Hospital, 7 Weiwu Road, Zhengzhou, Henan 450003, P.R. China, E-mail: <email>uvfnnnfuw49@163.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>5</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>31</day><month>3</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>31</day><month>3</month><year>2016</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. --><volume>11</volume><issue>5</issue><fpage>3361</fpage><lpage>3365</lpage><history><date date-type="received"><day>29</day><month>2</month><year>2016</year></date><date date-type="accepted"><day>30</day><month>3</month><year>2016</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Qi et al.</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license></permissions><abstract><p>The aim of the present study was to compare the recovery of sufentanil and remifentanil anesthesia by target-controlled infusion (TCI) in elderly patients with laparoscopic-assisted radical resection of colorectal cancer. The effect of anesthesia on patient stress response and cellular immune function was also observed. Elderly patients (n=192) who underwent laparoscopic radical resection of colorectal cancer between July 2014 and October 2015 were randomly divided into the sufentanil and remifentanil groups (n=96 per group). The two groups used sufentanil- and remifentanil-based anesthesia by TCI. The wake-up time, extubation time, orientation recovery time, vital signs, stress response, distribution of T-cell subsets and incidence of adverse reactions were recorded and compared. The wake-up and extubation times of the remifentanil group were significantly shorter than those of the sufentanil group. The difference of orientation recovery time was not statistically significant. The differences in heart rate, mean arterial pressure, and arterial oxygen saturation following anesthesia and during surgery and those prior to anesthesia of the sufentanil group were not statistically significant. However, those of the remifentanil group significantly improved following anesthesia. The concentrations of glucose, cortisol (COR), and interleukin-6 and C-reactive protein were stable in the sufentanil group, whereas the indices in the remifentanil group had a tendency of increasing during the anesthesia and surgery, and had a longer postoperative recovery time. The decreasing degree of T-cell subsets in the sufentanil group was significantly lower than that in the remifentanil group, and had a short recovery of cellular immunity following surgery. The adverse reactions rate during anesthesia of the remifentanil group was significantly higher than that of the sufentanil group. In conclusion, sufentanil- and remifentanil-based anesthesia with TCI has certain advantages, including improved recovery effect, less stress response, less inhibition of cellular immunity and fewer adverse reactions. It has the potential to become the first choice of anesthetic in the clinic for elderly patients who undergo laparoscopic radical resection for colorectal cancer.</p></abstract><kwd-group><kwd>target controlled infusion</kwd><kwd>sufentanil</kwd><kwd>remifentanil</kwd><kwd>laparoscope</kwd><kwd>colorectal cancer</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Colorectal cancer is one of the most common types of digestive tract tumors affecting 1.23 million individuals per year (9.7% of overall cancers) and is the fourth most common cause of mortality from cancer worldwide (608,000 cases, 8% of overall cancer deaths) (<xref rid="b1-ol-0-0-4394" ref-type="bibr">1</xref>). Currently, laparoscopic radical resection is the most widely used clinical treatment for colorectal cancer, however, it causes great discomfort for the patient (<xref rid="b2-ol-0-0-4394" ref-type="bibr">2</xref>). To improve the quality of anesthesia in the laparoscopic radical resection of colorectal cancer is a challenge for the medical field (<xref rid="b3-ol-0-0-4394" ref-type="bibr">3</xref>,<xref rid="b4-ol-0-0-4394" ref-type="bibr">4</xref>). Target-controlled infusion (TCI) is a new approach of anesthesia. TCI has the advantages of rapid drug delivery and simple operation (<xref rid="b5-ol-0-0-4394" ref-type="bibr">5</xref>). It has greatly improved the controllability and safety of clinical anesthesia, and has attracted increasing attention.</p><p>Sufentanil and remifentanil are opioid receptor agonists with a great analgesic effect during surgery (<xref rid="b6-ol-0-0-4394" ref-type="bibr">6</xref>&#x02013;<xref rid="b11-ol-0-0-4394" ref-type="bibr">11</xref>). However, there are few comparative studies available on the application of the two agonists in the laparoscopic radical resection of colorectal cancer with TCI. The aim of the present study was to sufentanil and remifentanil anesthesia with TCI in the laparoscopic radical resection of colorectal cancer, and examine their impact on patient stress response and cellular immunity to provide a theoretical reference for clinical anesthesia.</p></sec><sec sec-type="subjects|methods"><title>Patients and methods</title><sec><title/><sec><title>General information</title><p>A total of 192 elderly patients were selected to perform laparoscopic radical resection of colorectal cancer between July 2014 and October 2015. The patients included 106 males and 86 females, aged 62&#x02013;81 years, with an average age of 74.3&#x000b1;3.1 years, and a weight of 54&#x02013;82 kg, with an average weight of 67.6&#x000b1;2.5 kg. The selected cases were confirmed as colorectal cancer following colonoscopy and pathological examination. Patients who had previously used opioid drugs or had an allergy to sufentanil and remifentanil, or had serious damage of the heart, lung, liver, kidney function or other malignant tumor were excluded. The patients were divided randomly into the sufentanil and remifentanil groups (n=96 per group). The differences between the two groups with regard to gender, age and weight were not statistically significant (P&#x0003e;0.05), which was comparable.</p></sec><sec><title>Method</title><p>Prior to surgery, electrocardiogram and monitoring of vital signs were implemented in the two groups of patients, and an intramuscular injection of atropine (0.5 mg) and sodium phenobarbital (0.1 g) was performed. After 3 min of breathing with oxygen mask, rapid establishment of venous access and anesthesia induction was performed.</p><p>The sufentanil group used TCI sufentanil anesthesia (Langfang branch of Sinopharm Chemical Reagent Co., Ltd.; national medicine permission no. H20123298; Shanghai, China) at a concentration of 0.4 &#x000b5;g/l. Propofol was produced by Xi'an Libang Pharmaceutical Co., Ltd. (national medicine permission no. H20123318; Xi'an, China) at a concentration of 4 mg/l. Mechanical ventilation was carried out when plasma concentration of patients was in a state of equilibrium. During surgery, the concentration of propofol was controlled at 4 mg/l and rocuronium bromide, produced by Zhejiang Xianju Pharmaceutical Co., Ltd. (national medicine permission no. H20123188; Hangzhou, China), was injected continuously. The injection of sufentanil was ceased at the end of surgery.</p><p>The remifentanil group used TCI remifentanil anesthesia (Yichang Humanwell Pharmaceutical Co., Ltd.; national medicine permission no. H20030197; Yichang, China), at a concentration of 4.0 &#x000b5;g/l. The specific surgical process was the same as that of the sufentanil group. The injection of remifentanil was ceased at the end surgery. Temperature-holding nursing was implemented for the two groups. After patients regained their respiratory function and consciousness, catheters were removed and patients were sent to the recovery room.</p></sec><sec><title>Observation index</title><p>Observation indices were recorded for wake-up time, extubation time, orientation recovery time and adverse reactions, as well as vital signs [heart rate (HR), mean arterial pressure (MAP), arterial oxygen saturation (SpO<sub>2</sub>)] prior to (T<sub>0</sub>) and after (T<sub>1</sub>) anesthesia, at the end of surgery (T<sub>2</sub>) and 24 h after surgery (T<sub>3</sub>), 72 h after surgery (T<sub>4</sub>). The distribution of the stress response index [cortisol (COR), interleukin (IL)-6 and IL-10, glucose (GLU)] and T-lymphocyte subsets (CD3, CD4, CD8 and CD4/CD8).</p></sec><sec><title>Statistical analysis</title><p>SPSS 21.0 software (IBM SPSS, Armonk, NY, USA) was used for data analysis. Measurement data were presented as mean &#x000b1; standard deviation and differences between the two groups were determined by the t-test. Enumeration data were presented as a percentage and comparisons between groups were made using the &#x003c7;<sup>2</sup> test. P&#x0003c;0.05 was considered to indicate statistically significant results.</p></sec></sec></sec><sec sec-type="results"><title>Results</title><sec><title/><sec><title>Comparison of the quality of anesthesia recovery in the two groups</title><p>The wake-up and extubation times of the remifentanil group were significantly lower than those in the sufentanil group (P&#x0003c;0.01), and the difference of orientation recovery time in the two groups was not statistically significant (P&#x0003e;0.05; <xref rid="tI-ol-0-0-4394" ref-type="table">Table I</xref>).</p></sec><sec><title>Comparison of the changes of vital signs in the two groups</title><p>The differences of vital signs (HR, MAP, SpO<sub>2</sub>) after the anesthesia (T<sub>1</sub>) and at the end of surgery (T<sub>2</sub>) were not statistically significant (P&#x0003e;0.05). However, the remifentanil group had obvious changes after anesthesia (T<sub>1</sub>) and at the end of surgery (T<sub>2</sub>) in that HR improved, whereas MAP and SpO<sub>2</sub> significantly decreased (P&#x0003c;0.05; <xref rid="tII-ol-0-0-4394" ref-type="table">Table II</xref>).</p></sec><sec><title>Comparison of stress response indices in the two groups</title><p>The concentration of GLU, COR, IL-6 and C-reactive protein (CRP) of patients in the sufentanil group maintained stability, while the indices in the remifentanil group exhibited an increasing trend during the process of anesthesia and surgery, with a longer recovery following surgery. The differences of indices of GLU, COR, IL-6 and CRP between the two groups in T<sub>0</sub> were not statistically significant (P&#x0003e;0.05). However, statistical significance was observed for (P&#x0003c;0.05) in T<sub>1</sub>, T<sub>2</sub>, T<sub>3</sub>, T<sub>4</sub> (<xref rid="tIII-ol-0-0-4394" ref-type="table">Table III</xref>).</p></sec><sec><title>Distribution of T-cell subsets in the two groups</title><p>The degree of reduction of T-lymphocyte subsets in the sufentanil group was lower than that in the remifentanil group, with the sufentanil group having a shorter recovery of cell immune function. The differences of indices of CD3, CD4, CD8, and CD4/CD8 between the two groups in T<sub>0</sub> were not statistically significant (P&#x0003e;0.05), whereas, there was statistical significance (P&#x0003c;0.05) for T<sub>1</sub>, T<sub>2</sub>, T<sub>3</sub>, T<sub>4</sub> (<xref rid="tIV-ol-0-0-4394" ref-type="table">Table IV</xref>).</p></sec><sec><title>Comparison of adverse reactions in the two groups</title><p>Adverse reactions rate in the sufentanil group during the wake-up process was significantly lower than that in the remifentanil group (P&#x0003c;0.05; <xref rid="tV-ol-0-0-4394" ref-type="table">Table V</xref>).</p></sec></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Sufentanil is a type of narcotic drug and opioid receptor agonist, and contains citrate as the main pharmacological component (<xref rid="b2-ol-0-0-4394" ref-type="bibr">2</xref>&#x02013;<xref rid="b4-ol-0-0-4394" ref-type="bibr">4</xref>). Sufentanil is easily transferred through the blood-brain barrier with its high lipid solubility, and can bind with plasma protein for a good analgesic effect, with a longer interval for anesthesia (<xref rid="b12-ol-0-0-4394" ref-type="bibr">12</xref>,<xref rid="b13-ol-0-0-4394" ref-type="bibr">13</xref>). Refentanil as an opioid agonist is easily hydrolyzed in human tissues and blood, which has characteristics of rapid onset, short duration of anesthesia and no accumulation inside the human body (<xref rid="b14-ol-0-0-4394" ref-type="bibr">14</xref>).</p><p>The findings of the present study have shown that the wake-up and extubation times of the remifentanil group were significantly longer than those in the sufentanil group (P&#x0003c;0.01). The difference in orientation recovery time between two groups had no statistical significance (P&#x0003e;0.05). Sufentanil injection can be ceased at the end of surgery for its brief duration in the body and short biological half-life, which is controllable in the clinic.</p><p>Change of vital signs is an important indicator of surgical anesthesia. The present findings showed that the differences of HR, MAP, SpO<sub>2</sub> in T<sub>1</sub> and T<sub>2</sub> were not statistically significant in the sufentanil group compared with those prior to surgery (P&#x0003e;0.05). However, in the remifentanil group those parameters have obviously altered following surgery. HR increased significantly while MAP and SpO<sub>2</sub> decreased significantly in T<sub>1</sub> and T<sub>2</sub> compared with those prior to surgery (P&#x0003c;0.05). Therefore, sufentanil-based anesthesia with TCI maintains perioperative vital signs in a stable condition and hardly affected patient respiratory function and hemodynamics indices.</p><p>Radical resection for colorectal cancer leads to stress response in patients (<xref rid="b15-ol-0-0-4394" ref-type="bibr">15</xref>,<xref rid="b16-ol-0-0-4394" ref-type="bibr">16</xref>). Stress response is a non-specific defense reaction that occurs in the human body when externally stimulated. Previous findings (<xref rid="b2-ol-0-0-4394" ref-type="bibr">2</xref>,<xref rid="b17-ol-0-0-4394" ref-type="bibr">17</xref>,<xref rid="b18-ol-0-0-4394" ref-type="bibr">18</xref>) have shown that, stress responses initiated from anesthesia and surgery occur during the perioperative period, with a certain impact on recovery of patients following surgery. Serum COR and blood GLU can reflect t the intensity of stress response in the human body and IL-6 and IL-10 are important cytokines that are involved in the inflammatory response and injury repair and reflect the degree of human stress (<xref rid="b19-ol-0-0-4394" ref-type="bibr">19</xref>).</p><p>In the present study, the concentration of GLU, COR, IL-6 and CRP of patients in the sufentanil group maintained stability, whereas this concentration was increased during anesthesia and surgery in the remifentanil group, and the latter group had a longer recovery period following surgery. The differences of indices of GLU, COR, IL-6, and CRP for the two groups in T<sub>0</sub> were not statistically significant (P&#x0003e;0.05), but there was significance for T<sub>1</sub>, T<sub>2</sub>, T<sub>3</sub> and T<sub>4</sub> (P&#x0003c;0.05). This result suggested that sufentanil is able to maintain the blood GLU and COR in a stable condition and has much less stress response than remifentanil.</p><p>T lymphocytes and their subsets are the main immune active cells in the body's anti-tumor immunity, of which CD3 can effectively recognize the role of antigen, and is expressed on the surface of mature T lymphocytes. CD4 assists human B-cells to further differentiate and produce antibodies, while CD8 inhibits T-cell proliferation. CD4 and CD8 are expressed on the surface of suppressor cells and cytotoxic T lymphocytes (<xref rid="b20-ol-0-0-4394" ref-type="bibr">20</xref>&#x02013;<xref rid="b22-ol-0-0-4394" ref-type="bibr">22</xref>). The degree of immune function disorder is defined by the ratio CD4/CD8. In the present study, the degree of reduction of T-lymphocyte subsets in the sufentanil group was significantly lower than that in the remifentanil group, with a rapid recovery of cellular immune function. The differences of indices of CD3, CD4, CD8, and the CD4/CD8 ratio in T<sub>0</sub> exhibited no statistical significance (P&#x0003e;0.05), whereas statistical significance was identified for T<sub>1</sub>, T<sub>2</sub>, T<sub>3</sub>, T<sub>4</sub> (P&#x0003c;0.05). Thus, TCI of sufentanil anesthesia for laparoscopic radical resection for colorectal cancer effectively inhibits the cellular immune function, which recovers in a short time after surgery.</p><p>The present study analyzed adverse reactions in the process of wake-up and recovery. The results have shown that the incidence of adverse reactions, which include coughing and dysphoria, in the sufentanil group was significantly lower than that in the remifentanil group (P&#x0003c;0.05). Therefore, the TCI of sufentanil anesthesia is safe and reliable with few side effects. Thus, TCI of sufentanil anesthesia maintains stable hemodynamic and respiratory function and causes less stress response, less inhibition of cellular immunity and fewer side effects in its application. It thus has the potential to become the first choice of anesthesic to be used in the clinic for elderly patients who undergo laparoscopic radical resection for colorectal cancer and therefore may be promoted in the clinic.</p></sec></body><back><ref-list><title>References</title><ref id="b1-ol-0-0-4394"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolatkhah</surname><given-names>R</given-names></name><name><surname>Somi</surname><given-names>MH</given-names></name><name><surname>Bonyadi</surname><given-names>MJ</given-names></name><name><surname>Asvadi</surname><given-names>KI</given-names></name><name><surname>Farassati</surname><given-names>F</given-names></name><name><surname>Dastgiri</surname><given-names>S</given-names></name></person-group><article-title>Colorectal cancer in Iran: Molecular epidemiology and screening strategies</article-title><source>J Cancer Epidemiol</source><volume>2015</volume><fpage>643020</fpage><year>2015</year><pub-id pub-id-type="doi">10.1155/2015/643020</pub-id><pub-id pub-id-type="pmid">25685149</pub-id></element-citation></ref><ref id="b2-ol-0-0-4394"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>LG</given-names></name><name><surname>Pan</surname><given-names>JH</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Kang</surname><given-names>F</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name></person-group><article-title>Effects of different doses of sufentanil and remifentanil combined with propofol in target-controlled infusion on stress reaction in elderly patients</article-title><source>Exp Ther Med</source><volume>5</volume><fpage>807</fpage><lpage>812</lpage><year>2013</year><pub-id pub-id-type="pmid">23407772</pub-id></element-citation></ref><ref id="b3-ol-0-0-4394"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeganeh</surname><given-names>N</given-names></name><name><surname>Roshani</surname><given-names>B</given-names></name><name><surname>Latifi</surname><given-names>H</given-names></name><name><surname>Almasi</surname><given-names>A</given-names></name></person-group><article-title>Comparison of target-controlled infusion of sufentanil and remifentanil in blunting hemodynamic response to tracheal intubation</article-title><source>J Inj Violence Res</source><volume>5</volume><fpage>101</fpage><lpage>107</lpage><year>2013</year><pub-id pub-id-type="doi">10.5249/jivr.v5i2.325</pub-id><pub-id pub-id-type="pmid">23416718</pub-id></element-citation></ref><ref id="b4-ol-0-0-4394"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lilot</surname><given-names>M</given-names></name><name><surname>Meuret</surname><given-names>P</given-names></name><name><surname>Bouvet</surname><given-names>L</given-names></name><name><surname>Caruso</surname><given-names>L</given-names></name><name><surname>Dabouz</surname><given-names>R</given-names></name><name><surname>Del&#x000e9;at-Besson</surname><given-names>R</given-names></name><name><surname>Rousselet</surname><given-names>B</given-names></name><name><surname>Thouverez</surname><given-names>B</given-names></name><name><surname>Zadam</surname><given-names>A</given-names></name><name><surname>Allaouchiche</surname><given-names>B</given-names></name><etal/></person-group><article-title>Hypobaric spinal anesthesia with ropivacaine plus sufentanil for traumatic femoral neck surgery in the elderly: A dose-response study</article-title><source>Anesth Analg</source><volume>117</volume><fpage>259</fpage><lpage>264</lpage><year>2013</year><pub-id pub-id-type="doi">10.1213/ANE.0b013e31828f29f8</pub-id><pub-id pub-id-type="pmid">23592605</pub-id></element-citation></ref><ref id="b5-ol-0-0-4394"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>An</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Lv</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Fang</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Immune cell populations decrease during craniotomy under general anesthesia</article-title><source>Anesth Analg</source><volume>113</volume><fpage>572</fpage><lpage>577</lpage><year>2011</year><pub-id pub-id-type="pmid">21813628</pub-id></element-citation></ref><ref id="b6-ol-0-0-4394"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heyse</surname><given-names>B</given-names></name><name><surname>Proost</surname><given-names>JH</given-names></name><name><surname>Schumacher</surname><given-names>PM</given-names></name><name><surname>Bouillon</surname><given-names>TW</given-names></name><name><surname>Vereecke</surname><given-names>HE</given-names></name><name><surname>Eleveld</surname><given-names>DJ</given-names></name><name><surname>Luginb&#x000fc;hl</surname><given-names>M</given-names></name><name><surname>Struys</surname><given-names>MM</given-names></name></person-group><article-title>Sevoflurane remifentanil interaction: Comparison of different response surface models</article-title><source>Anesthesiology</source><volume>116</volume><fpage>311</fpage><lpage>323</lpage><year>2012</year><pub-id pub-id-type="doi">10.1097/ALN.0b013e318242a2ec</pub-id><pub-id pub-id-type="pmid">22222473</pub-id></element-citation></ref><ref id="b7-ol-0-0-4394"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogino</surname><given-names>S</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Fuchs</surname><given-names>CS</given-names></name><name><surname>Dranoff</surname><given-names>G</given-names></name></person-group><article-title>Cancer immunology - analysis of host and tumor factors for personalized medicine</article-title><source>Nat Rev Clin Oncol</source><volume>8</volume><fpage>711</fpage><lpage>719</lpage><year>2011</year><pub-id pub-id-type="doi">10.1038/nrclinonc.2011.122</pub-id><pub-id pub-id-type="pmid">21826083</pub-id></element-citation></ref><ref id="b8-ol-0-0-4394"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uusitalo-Sepp&#x000e4;l&#x000e4;</surname><given-names>R</given-names></name><name><surname>Koskinen</surname><given-names>P</given-names></name><name><surname>Leino</surname><given-names>A</given-names></name><name><surname>Peuravuori</surname><given-names>H</given-names></name><name><surname>Vahlberg</surname><given-names>T</given-names></name><name><surname>Rintala</surname><given-names>EM</given-names></name></person-group><article-title>Early detection of severe sepsis in the emergency room: Diagnostic value of plasma C-reactive protein, procalcitonin, and interleukin-6</article-title><source>Scand J Infect Dis</source><volume>43</volume><fpage>883</fpage><lpage>890</lpage><year>2011</year><pub-id pub-id-type="doi">10.3109/00365548.2011.600325</pub-id><pub-id pub-id-type="pmid">21892899</pub-id></element-citation></ref><ref id="b9-ol-0-0-4394"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Byun</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name></person-group><article-title>Abuse potential of propofol used for sedation in gastric endoscopy and its correlation with subject characteristics</article-title><source>Korean J Anesthesiol</source><volume>65</volume><fpage>403</fpage><lpage>409</lpage><year>2013</year><pub-id pub-id-type="doi">10.4097/kjae.2013.65.5.403</pub-id><pub-id pub-id-type="pmid">24363842</pub-id></element-citation></ref><ref id="b10-ol-0-0-4394"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>TT</given-names></name><name><surname>Poon</surname><given-names>RT</given-names></name></person-group><article-title>Synchronous resections of primary colorectal tumor and liver metastasis by laparoscopic approach</article-title><source>World J Hepatol</source><volume>5</volume><fpage>298</fpage><lpage>301</lpage><year>2013</year><pub-id pub-id-type="pmid">23805353</pub-id></element-citation></ref><ref id="b11-ol-0-0-4394"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bismuth</surname><given-names>J</given-names></name><name><surname>Duran</surname><given-names>C</given-names></name></person-group><article-title>Bypass surgery in limb salvage: Inflow procedures</article-title><source>Methodist DeBakey Cardiovasc J</source><volume>9</volume><fpage>66</fpage><lpage>68</lpage><year>2013</year><pub-id pub-id-type="doi">10.14797/mdcj-9-2-66</pub-id><pub-id pub-id-type="pmid">23805336</pub-id></element-citation></ref><ref id="b12-ol-0-0-4394"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fechner</surname><given-names>J</given-names></name><name><surname>Ihmsen</surname><given-names>H</given-names></name><name><surname>Sch&#x000fc;ttler</surname><given-names>J</given-names></name><name><surname>Jeleazcov</surname><given-names>C</given-names></name></person-group><article-title>The impact of intra-operative sufentanil dosing on post-operative pain, hyperalgesia and morphine consumption after cardiac surgery</article-title><source>Eur J Pain</source><volume>17</volume><fpage>562</fpage><lpage>570</lpage><year>2013</year><pub-id pub-id-type="doi">10.1002/j.1532-2149.2012.00211.x</pub-id><pub-id pub-id-type="pmid">22927230</pub-id></element-citation></ref><ref id="b13-ol-0-0-4394"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Xia</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name></person-group><article-title>The effect of small dose sufentanil on emergence agitation in preschool children following sevoflurane anesthesia for elective repair of unilateral inguinal hernia</article-title><source>Saudi Med J</source><volume>34</volume><fpage>40</fpage><lpage>45</lpage><year>2013</year><pub-id pub-id-type="pmid">23299158</pub-id></element-citation></ref><ref id="b14-ol-0-0-4394"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeleazcov</surname><given-names>C</given-names></name><name><surname>Saari</surname><given-names>TI</given-names></name><name><surname>Ihmsen</surname><given-names>H</given-names></name><name><surname>Sch&#x000fc;ttler</surname><given-names>J</given-names></name><name><surname>Fechner</surname><given-names>J</given-names></name></person-group><article-title>Changes in total and unbound concentrations of sufentanil during target controlled infusion for cardiac surgery with cardiopulmonary bypass</article-title><source>Br J Anaesth</source><volume>109</volume><fpage>698</fpage><lpage>706</lpage><year>2012</year><pub-id pub-id-type="doi">10.1093/bja/aes253</pub-id><pub-id pub-id-type="pmid">22831891</pub-id></element-citation></ref><ref id="b15-ol-0-0-4394"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bidgoli</surname><given-names>J</given-names></name><name><surname>Delesalle</surname><given-names>S</given-names></name><name><surname>De Hert</surname><given-names>SG</given-names></name><name><surname>Reiles</surname><given-names>E</given-names></name><name><surname>Van der Linden</surname><given-names>PJ</given-names></name></person-group><article-title>A randomised trial comparing sufentanil versus remifentanil for laparoscopic gastroplasty in the morbidly obese patient</article-title><source>Eur J Anaesthesiol</source><volume>28</volume><fpage>120</fpage><lpage>124</lpage><year>2011</year><pub-id pub-id-type="doi">10.1097/EJA.0b013e3283405048</pub-id><pub-id pub-id-type="pmid">21088598</pub-id></element-citation></ref><ref id="b16-ol-0-0-4394"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Lim</surname><given-names>BG</given-names></name><name><surname>Park</surname><given-names>HY</given-names></name><name><surname>Kim</surname><given-names>NS</given-names></name></person-group><article-title>Sufentanil infusion before extubation suppresses coughing on emergence without delaying extubation time and reduces postoperative analgesic requirement without increasing nausea and vomiting after desflurane anesthesia</article-title><source>Korean J Anesthesiol</source><volume>62</volume><fpage>512</fpage><lpage>517</lpage><year>2012</year><pub-id pub-id-type="doi">10.4097/kjae.2012.62.6.512</pub-id><pub-id pub-id-type="pmid">22778885</pub-id></element-citation></ref><ref id="b17-ol-0-0-4394"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caba&#x000f1;ero</surname><given-names>D</given-names></name><name><surname>Puig</surname><given-names>MM</given-names></name></person-group><article-title>Immediate and delayed remifentanil-induced hypersensitivity</article-title><source>Anesth Analg</source><volume>115</volume><fpage>977</fpage><lpage>978</lpage><comment>author reply 978&#x02013;979</comment><year>2012</year><pub-id pub-id-type="doi">10.1213/ANE.0b013e318263ca82</pub-id><pub-id pub-id-type="pmid">23002262</pub-id></element-citation></ref><ref id="b18-ol-0-0-4394"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Kim</surname><given-names>YD</given-names></name><name><surname>Kim</surname><given-names>JN</given-names></name></person-group><article-title>Antihyperalgesic effects of dexmedetomidine on high-dose remifentanil-induced hyperalgesia</article-title><source>Korean J Anesthesiol</source><volume>64</volume><fpage>301</fpage><lpage>307</lpage><year>2013</year><pub-id pub-id-type="doi">10.4097/kjae.2013.64.4.301</pub-id><pub-id pub-id-type="pmid">23646238</pub-id></element-citation></ref><ref id="b19-ol-0-0-4394"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez-Bono</surname><given-names>E</given-names></name><name><surname>Rohleder</surname><given-names>N</given-names></name><name><surname>Hellhammer</surname><given-names>DH</given-names></name><name><surname>Salvador</surname><given-names>A</given-names></name><name><surname>Kirschbaum</surname><given-names>C</given-names></name></person-group><article-title>Glucose but not protein or fat load amplifies the cortisol response to psychosocial stress</article-title><source>Horm Behav</source><volume>41</volume><fpage>328</fpage><lpage>333</lpage><year>2002</year><pub-id pub-id-type="doi">10.1006/hbeh.2002.1766</pub-id><pub-id pub-id-type="pmid">11971667</pub-id></element-citation></ref><ref id="b20-ol-0-0-4394"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yalcin</surname><given-names>N</given-names></name><name><surname>Uzun</surname><given-names>ST</given-names></name><name><surname>Reisli</surname><given-names>R</given-names></name><name><surname>Borazan</surname><given-names>H</given-names></name><name><surname>Otelcioglu</surname><given-names>S</given-names></name></person-group><article-title>A comparison of ketamine and paracetamol for preventing remifentanil induced hyperalgesia in patients undergoing total abdominal hysterectomy</article-title><source>Int J Med Sci</source><volume>9</volume><fpage>327</fpage><lpage>333</lpage><year>2012</year><pub-id pub-id-type="doi">10.7150/ijms.4222</pub-id><pub-id pub-id-type="pmid">22745573</pub-id></element-citation></ref><ref id="b21-ol-0-0-4394"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiefenthaler</surname><given-names>W</given-names></name><name><surname>Pehboeck</surname><given-names>D</given-names></name><name><surname>Hammerle</surname><given-names>E</given-names></name><name><surname>Kavakebi</surname><given-names>P</given-names></name><name><surname>Benzer</surname><given-names>A</given-names></name></person-group><article-title>Lung function after total intravenous anaesthesia or balanced anaesthesia with sevoflurane</article-title><source>Br J Anaesth</source><volume>106</volume><fpage>272</fpage><lpage>276</lpage><year>2011</year><pub-id pub-id-type="doi">10.1093/bja/aeq321</pub-id><pub-id pub-id-type="pmid">21062790</pub-id></element-citation></ref><ref id="b22-ol-0-0-4394"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bi</surname><given-names>SS</given-names></name><name><surname>Deng</surname><given-names>CH</given-names></name><name><surname>Zhou</surname><given-names>TY</given-names></name><name><surname>Guan</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>HQ</given-names></name><name><surname>Zhang</surname><given-names>LP</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name></person-group><article-title>Remifentanil-sevoflurane interaction models of circulatory response to laryngoscopy and circulatory depression</article-title><source>Br J Anaesth</source><volume>110</volume><fpage>729</fpage><lpage>740</lpage><year>2013</year><pub-id pub-id-type="doi">10.1093/bja/aes504</pub-id><pub-id pub-id-type="pmid">23388507</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="tI-ol-0-0-4394" orientation="portrait" position="float"><label>Table I.</label><caption><p>Comparison of the quality of anesthesia recovery in the two groups (min).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">No.</th><th align="center" valign="bottom" rowspan="1" colspan="1">Wake-up time</th><th align="center" valign="bottom" rowspan="1" colspan="1">Extubation time</th><th align="center" valign="bottom" rowspan="1" colspan="1">Orientation recovery time</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Sufentanil</td><td align="center" valign="top" rowspan="1" colspan="1">96</td><td align="center" valign="top" rowspan="1" colspan="1">17.3&#x000b1;7.7</td><td align="center" valign="top" rowspan="1" colspan="1">23.5&#x000b1;2.6</td><td align="center" valign="top" rowspan="1" colspan="1">16.4&#x000b1;3.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Remifentanil</td><td align="center" valign="top" rowspan="1" colspan="1">96</td><td align="center" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;8.7&#x000b1;3.4</td><td align="center" valign="top" rowspan="1" colspan="1">13.1&#x000b1;1.8</td><td align="center" valign="top" rowspan="1" colspan="1">15.5&#x000b1;3.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003e;0.05</td></tr></tbody></table></table-wrap><table-wrap id="tII-ol-0-0-4394" orientation="portrait" position="float"><label>Table II.</label><caption><p>Comparison of vital signs in the two groups (n=96).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">Vital signs</th><th align="center" valign="bottom" rowspan="1" colspan="1">T<sub>0</sub></th><th align="center" valign="bottom" rowspan="1" colspan="1">T<sub>1</sub></th><th align="center" valign="bottom" rowspan="1" colspan="1">T<sub>2</sub></th><th align="center" valign="bottom" rowspan="1" colspan="1">T<sub>3</sub></th><th align="center" valign="bottom" rowspan="1" colspan="1">T<sub>4</sub></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Sufentanil</td><td align="center" valign="top" rowspan="1" colspan="1">HR, min</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">74&#x000b1;4</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">75&#x000b1;6<sup><xref rid="tfn2-ol-0-0-4394" ref-type="table-fn">a</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">77&#x000b1;4<sup><xref rid="tfn2-ol-0-0-4394" ref-type="table-fn">a</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">74&#x000b1;5</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">73&#x000b1;4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Remifentanil</td><td rowspan="1" colspan="1"/><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">75&#x000b1;3</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">82&#x000b1;7<sup><xref rid="tfn3-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">85&#x000b1;4<sup><xref rid="tfn3-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">74&#x000b1;6</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">73&#x000b1;5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sufentanil</td><td align="center" valign="top" rowspan="1" colspan="1">MAP, mmHg</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">93&#x000b1;6</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">91&#x000b1;8<sup><xref rid="tfn2-ol-0-0-4394" ref-type="table-fn">a</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">92&#x000b1;8<sup><xref rid="tfn2-ol-0-0-4394" ref-type="table-fn">a</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">93&#x000b1;6</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">93&#x000b1;7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Remifentanil</td><td rowspan="1" colspan="1"/><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">92&#x000b1;5</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">85&#x000b1;7<sup><xref rid="tfn3-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">87&#x000b1;6<sup><xref rid="tfn3-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">92&#x000b1;5</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">92&#x000b1;6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sufentanil</td><td align="center" valign="top" rowspan="1" colspan="1">SpO<sub>2</sub> (%)</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">95&#x000b1;2</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">94&#x000b1;3<sup><xref rid="tfn2-ol-0-0-4394" ref-type="table-fn">a</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">95&#x000b1;2<sup><xref rid="tfn2-ol-0-0-4394" ref-type="table-fn">a</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">94&#x000b1;6</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">95&#x000b1;1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Remifentanil</td><td rowspan="1" colspan="1"/><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">94&#x000b1;1</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">89&#x000b1;2<sup><xref rid="tfn3-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">91&#x000b1;3<sup><xref rid="tfn3-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">94&#x000b1;4</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">94&#x000b1;2</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-ol-0-0-4394"><p>Compared with T<sub>0</sub></p></fn><fn id="tfn2-ol-0-0-4394"><label>a</label><p>P&#x0003e;0.05</p></fn><fn id="tfn3-ol-0-0-4394"><label>b</label><p>P&#x0003c;0.05. HR, heart rate; MAP, mean arterial pressure; SpO<sub>2</sub>, arterial oxygen saturation.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tIII-ol-0-0-4394" orientation="portrait" position="float"><label>Table III.</label><caption><p>Stress response indices in the two groups (n=96).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">Stress response index</th><th align="center" valign="bottom" rowspan="1" colspan="1">T0</th><th align="center" valign="bottom" rowspan="1" colspan="1">T1</th><th align="center" valign="bottom" rowspan="1" colspan="1">T2</th><th align="center" valign="bottom" rowspan="1" colspan="1">T3</th><th align="center" valign="bottom" rowspan="1" colspan="1">T4</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Sufentanil</td><td align="center" valign="top" rowspan="1" colspan="1">COR, &#x000b5;g/l</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">205.71&#x000b1;19.42<sup><xref rid="tfn5-ol-0-0-4394" ref-type="table-fn">a</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">227.55&#x000b1;24.72<sup><xref rid="tfn6-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">245.23&#x000b1;27.51<sup><xref rid="tfn6-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">212.46&#x000b1;20.13<sup><xref rid="tfn6-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">207.58&#x000b1;19.32<sup><xref rid="tfn6-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Remifentanil</td><td rowspan="1" colspan="1"/><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">205.36&#x000b1;21.62</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">231.68&#x000b1;23.41</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">256.45&#x000b1;26.15</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">236.92&#x000b1;23.84</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">211.37&#x000b1;21.19</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sufentanil</td><td align="center" valign="top" rowspan="1" colspan="1">IL-6, pg/ml</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">46.52&#x000b1;3.17<sup><xref rid="tfn5-ol-0-0-4394" ref-type="table-fn">a</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">51.54&#x000b1;4.67<sup><xref rid="tfn6-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">64.17&#x000b1;5.22<sup><xref rid="tfn6-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">48.73&#x000b1;4.01<sup><xref rid="tfn6-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">47.67&#x000b1;3.72<sup><xref rid="tfn6-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Remifentanil</td><td rowspan="1" colspan="1"/><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">47.12&#x000b1;3.24</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">57.14&#x000b1;5.13</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">71.76&#x000b1;6.21</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">57.58&#x000b1;4.51</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">52.12&#x000b1;4.03</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sufentanil</td><td align="center" valign="top" rowspan="1" colspan="1">CRP, mg/l</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">4.35&#x000b1;0.33<sup><xref rid="tfn5-ol-0-0-4394" ref-type="table-fn">a</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">5.21&#x000b1;0.42<sup><xref rid="tfn6-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">6.12&#x000b1;0.53<sup><xref rid="tfn6-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">5.37&#x000b1;0.44<sup><xref rid="tfn6-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">4.82&#x000b1;0.37<sup><xref rid="tfn6-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Remifentanil</td><td rowspan="1" colspan="1"/><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">4.31&#x000b1;0.34</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">7.87&#x000b1;0.75</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">9.17&#x000b1;0.67</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">10.75&#x000b1;1.16</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">6.54&#x000b1;0.77</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sufentanil</td><td align="center" valign="top" rowspan="1" colspan="1">GLU, mmol/l</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">4.58&#x000b1;0.37<sup><xref rid="tfn5-ol-0-0-4394" ref-type="table-fn">a</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">4.75&#x000b1;0.48<sup><xref rid="tfn6-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">5.04&#x000b1;0.46<sup><xref rid="tfn6-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">4.51&#x000b1;0.42<sup><xref rid="tfn6-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">4.47&#x000b1;0.36<sup><xref rid="tfn6-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Remifentanil</td><td rowspan="1" colspan="1"/><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">4.57&#x000b1;0.39</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">6.15&#x000b1;0.51</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">8.41&#x000b1;0.76</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">6.57&#x000b1;0.53</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">5.36&#x000b1;0.48</td></tr></tbody></table><table-wrap-foot><fn id="tfn4-ol-0-0-4394"><p>Comparison was made in the same period</p></fn><fn id="tfn5-ol-0-0-4394"><label>a</label><p>P&#x0003e;0.05</p></fn><fn id="tfn6-ol-0-0-4394"><label>b</label><p>P&#x0003c;0.05. COR, cortisol; IL, interleukin; CRP, C-reactive protein; GLU, glucose.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tIV-ol-0-0-4394" orientation="portrait" position="float"><label>Table IV.</label><caption><p>Distribution of T lymphocyte subsets in the two groups (n=96).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">Immunoglobulin</th><th align="center" valign="bottom" rowspan="1" colspan="1">T0</th><th align="center" valign="bottom" rowspan="1" colspan="1">T1</th><th align="center" valign="bottom" rowspan="1" colspan="1">T2</th><th align="center" valign="bottom" rowspan="1" colspan="1">T3</th><th align="center" valign="bottom" rowspan="1" colspan="1">T4</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Sufentanil</td><td align="center" valign="top" rowspan="1" colspan="1">CD3 (%)</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">60.74&#x000b1;5.28<sup><xref rid="tfn8-ol-0-0-4394" ref-type="table-fn">a</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">50.42&#x000b1;4.21<sup><xref rid="tfn9-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">47.16&#x000b1;3.73<sup><xref rid="tfn9-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">57.38&#x000b1;4.14<sup><xref rid="tfn9-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">60.37&#x000b1;5.13<sup><xref rid="tfn9-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Remifentanil</td><td rowspan="1" colspan="1"/><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">60.28&#x000b1;5.14</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">47.76&#x000b1;4.73</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">44.22&#x000b1;3.28</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">50.42&#x000b1;4.76</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">55.62&#x000b1;5.58</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sufentanil</td><td align="center" valign="top" rowspan="1" colspan="1">CD4 (%)</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">40.35&#x000b1;3.09<sup><xref rid="tfn8-ol-0-0-4394" ref-type="table-fn">a</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">37.42&#x000b1;2.84<sup><xref rid="tfn9-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">31.87&#x000b1;2.11<sup><xref rid="tfn9-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">33.59&#x000b1;2.83<sup><xref rid="tfn9-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">39.86&#x000b1;3.08<sup><xref rid="tfn9-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Remifentanil</td><td rowspan="1" colspan="1"/><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">41.46&#x000b1;3.17</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">31.33&#x000b1;2.36</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">27.14&#x000b1;1.74</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">29.22&#x000b1;2.18</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">33.04&#x000b1;2.26</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sufentanil</td><td align="center" valign="top" rowspan="1" colspan="1">CD8 (%)</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">26.15&#x000b1;1.74<sup><xref rid="tfn8-ol-0-0-4394" ref-type="table-fn">a</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">23.19&#x000b1;1.23<sup><xref rid="tfn9-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">22.27&#x000b1;1.09<sup><xref rid="tfn9-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">21.96&#x000b1;1.35<sup><xref rid="tfn9-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">24.67&#x000b1;1.55<sup><xref rid="tfn9-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Remifentanil</td><td rowspan="1" colspan="1"/><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">25.92&#x000b1;1.66</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">21.62&#x000b1;1.08</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">19.24&#x000b1;1.73</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">20.62&#x000b1;1.74</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">21.74&#x000b1;1.34</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sufentanil</td><td align="center" valign="top" rowspan="1" colspan="1">CD4/CD8</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">1.57&#x000b1;0.07<sup><xref rid="tfn8-ol-0-0-4394" ref-type="table-fn">a</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">1.46&#x000b1;0.05<sup><xref rid="tfn9-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">1.37&#x000b1;0.04<sup><xref rid="tfn9-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">1.44&#x000b1;0.05<sup><xref rid="tfn9-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">1.47&#x000b1;0.06<sup><xref rid="tfn9-ol-0-0-4394" ref-type="table-fn">b</xref></sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Remifentanil</td><td rowspan="1" colspan="1"/><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">1.55&#x000b1;0.06</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">1.27&#x000b1;0.03</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">1.13&#x000b1;0.02</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">1.27&#x000b1;0.04</td><td char="&#x000b1;" align="char" valign="top" rowspan="1" colspan="1">1.31&#x000b1;0.05</td></tr></tbody></table><table-wrap-foot><fn id="tfn7-ol-0-0-4394"><p>Comparison was made in the same period</p></fn><fn id="tfn8-ol-0-0-4394"><label>a</label><p>P&#x0003e;0.05</p></fn><fn id="tfn9-ol-0-0-4394"><label>b</label><p>P&#x0003c;0.05.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tV-ol-0-0-4394" orientation="portrait" position="float"><label>Table V.</label><caption><p>Comparison of adverse reactions in the two groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Group</th><th align="center" valign="bottom" rowspan="1" colspan="1">No.</th><th align="center" valign="bottom" rowspan="1" colspan="1">Coughing</th><th align="center" valign="bottom" rowspan="1" colspan="1">Dysphoria</th><th align="center" valign="bottom" rowspan="1" colspan="1">Nausea and vomiting</th><th align="center" valign="bottom" rowspan="1" colspan="1">Shivering</th><th align="center" valign="bottom" rowspan="1" colspan="1">Adverse reactions rate, %</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Sufentanil</td><td align="center" valign="top" rowspan="1" colspan="1">96</td><td align="center" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;5</td><td align="center" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;3</td><td align="center" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;6</td><td align="center" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;9</td><td align="center" valign="top" rowspan="1" colspan="1">25.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Refentanil</td><td align="center" valign="top" rowspan="1" colspan="1">96</td><td align="center" valign="top" rowspan="1" colspan="1">12</td><td align="center" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">15</td><td align="center" valign="top" rowspan="1" colspan="1">49.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.05</td></tr></tbody></table></table-wrap></floats-group></article>